Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA places clinical hold on Concert Pharmaceuticals’ hair loss drug
The FDA had previously informed the Company that it could initiate the Phase 2a clinical trial; however, subsequent to its initiation, but prior to dosing subjects, the FDA
The FDA had previously informed the Company that it could initiate the Phase 2a clinical trial; however, subsequent to its initiation, but prior to dosing subjects, the FDA
These data include results from pooled analyses of three Phase 1 expansion cohorts and from a Phase 1b/2 study, FORWARD II, evaluating mirvetuximab soravtansine in combination with Avastin
The companies will investigate the combination of CRS-207, Aduro’s LADD (live, attenuated double-deleted) based immunotherapy, with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, for the treatment of patients with malignant
The target indication for CIRARA is large hemispheric infarction (LHI), a severe form of ischemic stroke where brain swelling (cerebral edema) often leads to a disproportionately large share
The Commission will investigate whether Aspen has abused a dominant market position in breach of EU antitrust rules. Commissioner Margrethe Vestager, in charge of competition policy, said: "When
PhaseOut DMD aims to provide proof of concept for ezutromid through measures of a number of endpoints related to muscle structure, health and function. The Company believes the
The research was recently published in Nature Communications. In the case of cancer treatment, to target specific tumors in the body, scientists have developed techniques where drug molecules
Tenapanor is Ardelyx's investigational, minimally systemic, small-molecule NHE3 inhibitor. The T3MPO-1 trial achieved statistical significance for the primary endpoint and seven of eight secondary endpoints. The primary endpoint,
"The robust results from these three studies bring us one step closer to helping people experience more migraine-free days, an important treatment goal for those living with this
The grant, entitled "Cell2Sell – commercial scale next generation platform for allogeneic stem cell production", has been awarded under Innovate UK's Cell & Gene Therapies Industrial Manufacture grant